Download PDF

1. Company Snapshot

1.a. Company Description

Azenta, Inc.provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally.The company operates through two reportable segments, Life Sciences Products and Life Sciences Services.


The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows.The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development.This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services.


It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes.The company was formerly known as Brooks Automation, Inc.and changed its name to Azenta, Inc.


in December 2021.Azenta, Inc.was founded in 1978 and is headquartered in Chelmsford, Massachusetts.

Show Full description

1.b. Last Insights on AZTA

Breaking News: Azenta Inc reported Q1 2026 earnings on February 4 2026. The company announced financial results for the quarter ended December 31 2025. No specific numbers or details were provided in the data. Analysts at various firms have given recommendations on the stock. Wedbush Securities and Stifel upgraded or downgraded their rating . RBC Capital Markets analyst upgraded Azenta to Outperform from Sector Perform .

1.c. Company Highlights

2. Azenta's Q1 2026 Earnings: A Mixed Bag

Azenta reported a total revenue of $149 million, down 1% organically, with a 2% headwind from foreign exchange. The decline was primarily due to underutilized lab capacity, driven by lower North America volumes, and additional costs related to rework on automated storage projects. Adjusted EBITDA was 8.5% or $12.7 million, down $3.3 million from the prior year. The EPS came in at $0.09, missing estimates of $0.11.

Publication Date: Feb -06

📋 Highlights
  • Q1 Revenue Decline:: Organic revenue fell 1% to $149M, with a 2% FX headwind, driven by underutilized lab capacity and lower North American volumes.
  • Adjusted EBITDA Drop:: EBITDA margin at 8.5% ($12.7M) declined $3.3M YoY due to $2M store quality issues, $1M lab inefficiencies, and $700K nonrecurring charges.
  • 2026 Guidance:: Maintains 3-5% organic revenue growth and 300 bps EBITDA margin expansion target, with 200 bps gross profit improvement from volume/productivity.
  • Segment Performance:: Sample Management Solutions revenue flat (-2% organic), Multiomics up 1% (flat organic), with NexGen sequencing growth offsetting Sanger decline.
  • Balance Sheet Strength:: $571M cash/cash equivalents and marketable securities, no debt, with $250M share repurchase authorization as capital deployment option.

Segment Performance

In Sample Management Solutions, revenue was flat on a reported basis and down 2% organically, due to softness in automated stores and cryo. In Multiomics, revenue was up 1% on a reported basis and flat organically, with next-generation sequencing and gene synthesis showing growth. The company is confident in its ability to improve margins, but notes that customer dynamics are outside of its control.

Guidance and Outlook

Azenta reaffirmed its guidance for fiscal 2026, with organic revenue growth expected in the range of 3% to 5%, and adjusted EBITDA margin expansion of approximately 300 basis points. The company expects to see an uplift in revenue in the second half, driven by the second-half ramp, with growth driven by volume, ABS, and productivity. Analysts estimate next year's revenue growth at 5.4%.

Valuation

With a P/E Ratio of -21.47 and an EV/EBITDA of 26.28, Azenta's valuation multiples suggest that the market is pricing in a significant improvement in earnings. The company's ROE and ROIC are currently negative, at -3.49% and -4.46%, respectively. The market seems to be expecting a turnaround, with the stock potentially undervalued given its P/B Ratio of 0.74 and P/S Ratio of 2.16.

Management's Strategy

As John Marotta, President and CEO, noted, "We're continuing our company-wide turnaround and transformation, and we're excited about creating long-term shareholder value over the next few years." The company is focusing on operational excellence, accelerating growth, expanding margins, and strategic capital deployment. With a strong balance sheet, including $571 million in cash, cash equivalents, and marketable securities, and no debt outstanding, Azenta is well-positioned to execute on its priorities.

3. NewsRoom

Card image cap

Azenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research Infrastructure

Feb -09

Source: prnewswire.com

Card image cap

Azenta, Inc. (AZTA) Q1 2026 Earnings Call Transcript

Feb -04

Source: seekingalpha.com

Card image cap

Azenta Reports First Quarter Results for Fiscal 2026, Ended December 31, 2025

Feb -04

Source: prnewswire.com

Card image cap

Privia Health Group (NASDAQ:PRVA) & Azenta (NASDAQ:AZTA) Financial Analysis

Feb -02

Source: defenseworld.net

Card image cap

Head-To-Head Survey: 10x Genomics (NASDAQ:TXG) & Azenta (NASDAQ:AZTA)

Jan -31

Source: defenseworld.net

Card image cap

Azenta Announces Fiscal 2026 First Quarter Conference Call and Webcast

Jan -21

Source: prnewswire.com

Card image cap

Azenta, Inc. (NASDAQ:AZTA) Receives $41.83 Average Target Price from Analysts

Jan -14

Source: defenseworld.net

Card image cap

New Strong Sell Stocks for January 8th

Jan -08

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (5.92%)

6. Segments

Life Sciences Services

Expected Growth: 5%

Azenta's Life Sciences Services segment growth is driven by increasing demand for gene and cell therapy development, expansion of biopharma customers, and strategic acquisitions. The segment benefits from the growing need for outsourced services, such as bioprocessing and analytical testing, and Azenta's expertise in these areas. Additionally, the company's investments in digitalization and automation enhance its service offerings, further fueling growth.

Life Sciences Products

Expected Growth: 7%

Azenta's Life Sciences Products segment growth is driven by increasing demand for gene therapy and gene editing, expansion in bioprocessing and cell therapy, and growing adoption of automated sample management solutions. Additionally, strategic acquisitions and partnerships, as well as investments in R&D, contribute to the 7% growth rate.

7. Detailed Products

CryoStore

A cryogenic storage system designed for the long-term preservation of biological samples at extremely low temperatures.

CryoPod

A portable, cryogenic storage container for the safe transportation of biological samples.

IScan

A fully automated, high-capacity storage system for biological samples, featuring advanced inventory management and tracking capabilities.

DataSmart

A comprehensive, cloud-based software platform for managing and tracking biological samples, including inventory management, tracking, and analytics.

CryoPod Express

A compact, portable cryogenic storage container for the safe transportation of small quantities of biological samples.

8. Azenta, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Azenta, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the evolving nature of the biotechnology industry.

Bargaining Power Of Customers

Azenta, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are highly specialized, making it difficult for customers to switch to alternative suppliers.

Bargaining Power Of Suppliers

Azenta, Inc. relies on a few key suppliers for critical components, which gives them some bargaining power. However, the company's strong relationships with suppliers and its ability to negotiate contracts mitigate this risk.

Threat Of New Entrants

The biotechnology industry has high barriers to entry, including significant capital requirements, complex regulatory frameworks, and the need for specialized expertise. This limits the threat of new entrants.

Intensity Of Rivalry

The biotechnology industry is highly competitive, with many established players and new entrants vying for market share. Azenta, Inc. faces intense competition from companies with similar products and services.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 2.71%
Debt Cost 3.95%
Equity Weight 97.29%
Equity Cost 11.52%
WACC 11.31%
Leverage 2.79%

11. Quality Control: Azenta, Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Merit Medical Systems

A-Score: 4.2/10

Value: 2.7

Growth: 7.3

Quality: 5.3

Yield: 0.0

Momentum: 2.5

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
DENTSPLY SIRONA

A-Score: 4.2/10

Value: 7.3

Growth: 1.6

Quality: 2.8

Yield: 7.0

Momentum: 1.0

Volatility: 5.3

1-Year Total Return ->

View Full Report
Stock-Card
Teleflex

A-Score: 3.7/10

Value: 6.2

Growth: 3.4

Quality: 5.1

Yield: 1.0

Momentum: 1.0

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Repligen

A-Score: 3.6/10

Value: 0.4

Growth: 5.0

Quality: 5.1

Yield: 0.0

Momentum: 7.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Azenta

A-Score: 3.3/10

Value: 5.1

Growth: 4.4

Quality: 4.8

Yield: 0.0

Momentum: 2.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Cooper

A-Score: 3.2/10

Value: 2.6

Growth: 2.0

Quality: 5.8

Yield: 0.0

Momentum: 2.0

Volatility: 6.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

29.8$

Current Price

29.8$

Potential

-0.00%

Expected Cash-Flows